本文關(guān)鍵詞： FGF23 Klotho CKD CVD　出處：《重慶醫(yī)科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：慢性腎臟病(Chronic kidney diease,CKD)患者由于存在骨-礦物質(zhì)代謝紊亂(Mineral Bone Disorder,MDB)而使其面臨高心血管疾病(Cardiovascular disease,CVD)發(fā)病率和死亡風(fēng)險,但這些高風(fēng)險并不能用傳統(tǒng)的CVD危險因素來解釋。深入了解終末期腎臟病(End-stage renal disease,ESRD)患者CVD危險因素及其與左心室肥厚(Left ventricular hyoertrophy,LVH)、心力衰竭、房顫、血管鈣化等心血管事件發(fā)病機(jī)制的關(guān)系,可在診斷和治療由于MBD導(dǎo)致的心血管疾病方面帶來很大幫助,從而ESRD患者的生存率。新近的藥物治療方法雖然可使ESRD患者在心血管并發(fā)癥方面有一定的臨床獲益,但仍然存在爭議。該綜述將討論有關(guān)成纖維生長因子23(Fibroblast growth factor23,FGF23)、Klotho蛋白(Klotho protein,Klotho)的基礎(chǔ)和臨床研究,并闡述其在CKD患者LVH、心力衰竭、房顫、血管鈣化等方面的作用、發(fā)病機(jī)制及治療。
[Abstract]:Patients with chronic kidney disease (Chronic kidney disease) are exposed to high incidence and death risk of cardiovascular disease due to the presence of bone mineral metabolism disorder mineral Bone disorder (MDBs). But these high risk factors can not be explained by traditional CVD risk factors. To understand the risk factors of CVD in patients with End-stage renal disease and its association with left ventricular hypertrophy, left ventricular hypertrophy, heart failure, atrial fibrillation, heart failure, atrial fibrillation. The relationship between cardiovascular events such as vascular calcification and other cardiovascular events can be of great help in the diagnosis and treatment of cardiovascular diseases caused by MBD. Therefore, the survival rate of patients with ESRD. Although the recent drug therapy can benefit the patients with ESRD in cardiovascular complications, This review will discuss the basic and clinical studies of fibroblast growth factor 23 FGF23 / Klotho protein Klotho protein Klotho, and its role in LVH, heart failure, atrial fibrillation and vascular calcification in patients with CKD.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R692;R54

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 Usama AA Sharaf El Din;Mona M Salem;Dina O Abdulazim;;FGF23 and inflammation[J];World Journal of Nephrology;2017年01期

，

本文編號：1551630